Pages that link to "Q43004818"

The following pages link to ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure (Q43004818):

Displaying 21 items.

• Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage (Q26773289) (← links)
• Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals (Q26782033) (← links)
• Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data (Q28481485) (← links)
• Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison. (Q30371705) (← links)
• Non-invasive diagnosis of advanced fibrosis and cirrhosis (Q30423320) (← links)
• Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. (Q30462755) (← links)
• Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. (Q34892910) (← links)
• WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients (Q35080930) (← links)
• Higher serum testosterone is associated with increased risk of advanced hepatitis C–related liver disease in males (Q36102410) (← links)
• Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. (Q36406176) (← links)
• Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients (Q36875826) (← links)
• Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference (Q37420413) (← links)
• Finasteride and methadone use and risk of advanced hepatitis C related liver disease (Q38016312) (← links)
• Can non-invasive assessment of liver fibrosis replace liver biopsy? (Q39677737) (← links)
• Prognostic value of liver fibrosis biomarkers: a meta-analysis (Q40621139) (← links)
• Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery (Q47245264) (← links)
• HCV-GenoFibrotest: A combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C (Q50557124) (← links)
• Impact of steatosis and inflammation definitions on the performance of NASH tests. (Q55069031) (← links)
• Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: A step toward the truth in the absence of a gold standard (Q58622618) (← links)
• What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI) (Q58622652) (← links)
• The Reliability of Fibro-test in Staging Orthotopic Liver Transplant Recipients with Recurrent Hepatitis C (Q91795092) (← links)